Ming-Sound Tsao1, Sophie Marguet2, Gwénaël Le Teuff2, Sylvie Lantuejoul2, Frances A Shepherd2, Lesley Seymour2, Robert Kratzke2, Stephen L Graziano2, Helmut H Popper2, Rafael Rosell2, Jean-Yves Douillard2, Thierry Le-Chevalier2, Jean-Pierre Pignon2, Jean-Charles Soria2, Elisabeth M Brambilla2. 1. Ming-Sound Tsao and Frances A. Shepherd, Princess Margaret Cancer Centre, University Health Network, and University of Toronto, Toronto; Lesley Seymour, NCIC Clinical Trials Group and Queen's University, Kingston, Ontario, Canada; Sophie Marguet, Gwénaël Le Teuff, Thierry Le-Chevalier, Jean-Pierre Pignon, and Jean-Charles Soria, Gustave Roussy, Villejuif; Sylvie Lantuejoul and Elisabeth M. Brambilla, Inserm U823, Centre Hospitalier Universitaire de Grenoble, Institut Albert Bonniot, Université Joseph Fourier, Grenoble; Jean-Yves Douillard, Centre René Gauducheau, Saint-Herblain, Nantes, France; Robert Kratzke, University of Minnesota, Minneapolis, MN; Stephen L. Graziano, SUNY Upstate Medical University, Syracuse, NY; Helmut H. Popper, Institute of Pathology, University Medical School of Graz, Graz, Austria; and Rafael Rosell, Catalan Institute of Oncology, Barcelona, Spain. ming.tsao@uhn.ca. 2. Ming-Sound Tsao and Frances A. Shepherd, Princess Margaret Cancer Centre, University Health Network, and University of Toronto, Toronto; Lesley Seymour, NCIC Clinical Trials Group and Queen's University, Kingston, Ontario, Canada; Sophie Marguet, Gwénaël Le Teuff, Thierry Le-Chevalier, Jean-Pierre Pignon, and Jean-Charles Soria, Gustave Roussy, Villejuif; Sylvie Lantuejoul and Elisabeth M. Brambilla, Inserm U823, Centre Hospitalier Universitaire de Grenoble, Institut Albert Bonniot, Université Joseph Fourier, Grenoble; Jean-Yves Douillard, Centre René Gauducheau, Saint-Herblain, Nantes, France; Robert Kratzke, University of Minnesota, Minneapolis, MN; Stephen L. Graziano, SUNY Upstate Medical University, Syracuse, NY; Helmut H. Popper, Institute of Pathology, University Medical School of Graz, Graz, Austria; and Rafael Rosell, Catalan Institute of Oncology, Barcelona, Spain.
Abstract
PURPOSE: The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and WHO is based on the predominant histologic pattern-lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or solid (SOL)-present in the tumor. This classification has not been tested in multi-institutional cohorts or clinical trials or tested for its predictive value regarding survival from adjuvant chemotherapy (ACT). PATIENTS AND METHODS: Of 1,766 patients in the IALT, JBR.10, CALGB 9633 (Alliance), and ANITA ACT trials included in the LACE-Bio study, 725 had adenocarcinoma. Histologies were reclassified according to the new classification and then collapsed into three groups (LEP, ACN/PAP, and MIP/SOL). Primary end point was overall survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS). Hazard ratios (HRs) and 95% CIs were estimated through multivariable Cox models stratified by trial. Prognostic value was estimated in the observation arm and predictive value by a treatment effect interaction with histologic subgroups. Significance level was set at .01 for pooled analysis. RESULTS: A total of 575 patients were included in this analysis. OS was not prognostically different between histologic subgroups, but univariable DFS and SDFS were worse for MIP/SOL compared with LEP or ACN/PAP subgroup (P < .01); this remained marginally significant after adjustment. MIP/SOL patients (but not ACN/PAP) derived DFS and SDFS but not OS benefit from ACT (OS: HR, 0.71; 95% CI, 0.51 to 0.99; interaction P = .18; DFS: HR, 0.60; 95% CI, 0.44 to 0.82; interaction P = < .01; and SDFS: HR, 0.59; 95% CI, 0.42 to 0.81; interaction P = .01). CONCLUSION: The new lung adenocarcinoma classification based on predominant histologic pattern was not predictive for ACT benefit for OS, but it seems predictive for disease-specific outcomes.
PURPOSE: The classification for invasive lung adenocarcinoma by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and WHO is based on the predominant histologic pattern-lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or solid (SOL)-present in the tumor. This classification has not been tested in multi-institutional cohorts or clinical trials or tested for its predictive value regarding survival from adjuvant chemotherapy (ACT). PATIENTS AND METHODS: Of 1,766 patients in the IALT, JBR.10, CALGB 9633 (Alliance), and ANITA ACT trials included in the LACE-Bio study, 725 had adenocarcinoma. Histologies were reclassified according to the new classification and then collapsed into three groups (LEP, ACN/PAP, and MIP/SOL). Primary end point was overall survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS). Hazard ratios (HRs) and 95% CIs were estimated through multivariable Cox models stratified by trial. Prognostic value was estimated in the observation arm and predictive value by a treatment effect interaction with histologic subgroups. Significance level was set at .01 for pooled analysis. RESULTS: A total of 575 patients were included in this analysis. OS was not prognostically different between histologic subgroups, but univariable DFS and SDFS were worse for MIP/SOL compared with LEP or ACN/PAP subgroup (P < .01); this remained marginally significant after adjustment. MIP/SOL patients (but not ACN/PAP) derived DFS and SDFS but not OS benefit from ACT (OS: HR, 0.71; 95% CI, 0.51 to 0.99; interaction P = .18; DFS: HR, 0.60; 95% CI, 0.44 to 0.82; interaction P = < .01; and SDFS: HR, 0.59; 95% CI, 0.42 to 0.81; interaction P = .01). CONCLUSION: The new lung adenocarcinoma classification based on predominant histologic pattern was not predictive for ACT benefit for OS, but it seems predictive for disease-specific outcomes.
Authors: Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli Journal: J Natl Cancer Inst Date: 2013-08-07 Impact factor: 13.506
Authors: Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Frances A Shepherd; Caroline Domerg; Pierre Hainaut; Pasi A Jänne; Jean-Pierre Pignon; Stephen Graziano; Jean-Yves Douillard; Elizabeth Brambilla; Thierry Le Chevalier; Lesley Seymour; Abderrahmane Bourredjem; Gwénaël Le Teuff; Robert Pirker; Martin Filipits; Rafael Rosell; Robert Kratzke; Bizhan Bandarchi; Xiaoli Ma; Marzia Capelletti; Jean-Charles Soria; Ming-Sound Tsao Journal: J Clin Oncol Date: 2013-04-29 Impact factor: 44.544